Roche Diagnostics Boosts Staff To Focus On Medical Genomics Research
This article was originally published in The Gray Sheet
Roche Diagnostics will bolster its genetic research efforts by adding a 100-person genomics staff as it seeks to capitalize on advances being made in the genomics field by shifting its R&D focus from clinical chemistry to molecular genetics.
You may also be interested in...
MiniMed is developing a follow-on version of its continuous glucose monitoring system (CGMS) that will be sold directly to patients, allowing them to monitor their own glucose levels, the firm said following FDA's June 16 approval of a non-consumer configuration as an adjunct to finger-stick blood glucose testing.
Roche is negotiating with potential buyers of Boehringer Mannheim's Closed Enzyme Donor Immuno Assay (CEDIA) reagents for drugs-of-abuse (DOA) testing to comply with conditions of a Feb. 24 Federal Trade Commission settlement. The FTC settlement cleared the way for Roche's $10.2 bil. acquisition of Corange, the parent company of Boehringer Mannheim and DePuy.
3D-printing company Carbon and in vitro diagnostics maker Resolution Medical announced plans to manufacture more than one million 3D-printed nasal swabs per week to test for COVID-19. See what Resolution Medical’s president Shawn Patterson said about it here.